TD Cowen raised the price target for the Halozyme Therapeutics Inc. (NASDAQ:HALO) stock to “an Outperform”. The rating was released on February 29, 2024, according to finviz. The research report from Goldman has downgraded the stock from Buy to Neutral, with a price target set at $45. The stock was upgraded by Piper Sandler, who disclosed in a research note on May 10, 2023, from Neutral to Overweight and set the price objective to $46. In their research brief published March 27, 2023, Berenberg analysts resumed the Halozyme Therapeutics Inc. stock to Buy with a price target of $58.
Historical Earnings Surprises and Revenue Forecasts
Profit is the most critical financial performance measure. Every investor in a business is looking forward to the earnings report as stock price to increase when earnings exceed market expectations and progressively decrease when earnings do not meet expectations. The firm reported an earnings per share (EPS) of $0.82 during the last quarter as opposed to a consensus estimate of $0.82, which indicates the company missed its estimate by $0, which implies that the company surprised the market by 0.00%. It appears that the average earnings per share estimate for the current quarter (ending in Mar 2024) is $0.76. This is an average of 6 analysts’ earnings, where the high earnings per share estimate is $0.83 and the low earnings per share estimate is $0.69. According to 9 analyst estimates, an average revenue estimate of $212.15M is projected for the current quarter with a high revenue estimate of $259.4M and a low estimate of $180.72M.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The latest trade, Performances and Moving Averages give us the following Picture
The firm’s stock price fluctuated -2.35% within the last five trades and 12.17% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the share price increased 1.53% in the last 6 months and 4.07% was added to its value over the previous 3 months. HALO stock is trading at a margin of -0.73%, 8.59% and 5.64% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.
As of the close of trading, HALO deals in the Healthcare domain. The stock is trading -10.27 percent below its 52-week high and 35.28 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is 17.5. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.
What Does Halozyme Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?
With regard to the profitability of the company, the operating margin is currently at 40.71 percent and the profit margin is 33.96 percent, and the company has reported a gross margin of 67.91 percent. The profit margin, also known as the revenue ratio or gross profit ratio, is an efficiency figure used to estimate the business’s profitability by comparing net income and sales. The higher the number, the more profits are generated for the company and vice versa.
The stock’s market cap achieved a total value of $5.13 billion as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value. The price-to-earnings ratio for Halozyme Therapeutics Inc. (NASDAQ:HALO) is 19.15. The price-to-earnings ratio is a method of assessing corporate values by comparing them to their per-share profit. Forward P/E stands at 9.09. Forward price-to-earnings is calculated using predicted earnings for the next financial year’s P/E determination. The stock has achieved an effective Price-to-Sales Ratio of 6.19 that mirrors the cost to be found for sales by the market. The firm managed a Price-to-Book ratio of 61.08, which equates the market value of a stock with its book value.
Is Insider Trading a Real Thing?
Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 1.08 percent of Halozyme Therapeutics Inc. shares are owned by insiders, and 98.70 percent are held by financial institutions. LaBarre Michael J., the SVP, CHIEF TECHNICAL OFFICER at Halozyme Therapeutics Inc. (HALO) has sold 10,000 shares of firm on Mar 13 ’24 at a price of $42.27 against the total amount of $0.42 million. In another inside trade, LaBarre Michael J., SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc. (NASDAQ:HALO) sold 10,000 shares of the firm on Mar 12 ’24 for a total worth of $0.42 million at a price of $41.64. An inside trade which took place on Feb 28 ’24, SVP, CHIEF TECHNICAL OFFICER of Halozyme Therapeutics Inc. LaBarre Michael J. sold 10,000 shares of firm against total price of $0.4 million at the cost of $39.55 per share.
